The effect of dexamethasone on accelerated recovery after total knee arthroplasty used a tourniquet: a prospective, double-blind, randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041061

Enrollment

Unknown

Registered

2020-12-17

Start date

2020-12-17

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

A:No tourniquet use+ topical dexamethasone combined with intravenous dexamethasone

B:Restrict tourniquet use: before osteotomy until prosthesis placement is complete, and during bone cement curing

C:Restrict tourniquet use+topical dexamethasone combined with intravenous dexamethasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients requiring unilateral primary TKA surgery due to severe osteoarthritis of the knee; (2) 40~80 years old; (3) Body mass index was 20~35 kg/m2; (4) the American Society of Anesthesiologists (American Society of Anesthesiologists, ASA) classification (anesthesia risk assessment) is I ~ III level.

Exclusion criteria

Exclusion criteria: (1) Simultaneous operation of both knee joints; (2) Patients with blood diseases, diabetes, malignant tumors and abnormal coagulation function; (3) Patients with a history of myocardial infarction, cerebral infarction, pulmonary embolism and other thrombosis; (4) Those who received anticoagulant therapy within 6 months before operation; (5) Persons with severe knee malformation and previous history of knee surgery (6) Persons allergic to narcotic drugs and sulfanilamide; (7) Alcoholism or long-term use of opioids; (8) Language impairment and inability to complete Visual analogue Scale (VAS); (9) Surgical limb neuropathy; (10) Persons with mental illness; (11) Patients with digestive tract ulcer.

Design outcomes

Primary

Measure	Time frame
The duration of surgery;The duration od tourniquet use;Postoperative dosage of remedial morphine hydrochloride;VAS pain score;Degree of knee joint swelling (leg circumference);Range of knee motion;Strength of lower limb muscles;LOS (length of stay);The incidence of adverse events;Intraoperative blood loss;Dominant blood loss;Hidden blood loss;Total perioperative blood loss;C-reactive protein;Interleukin - 6;	—

Measure

Time frame

The duration of surgery;The duration od tourniquet use;Postoperative dosage of remedial morphine hydrochloride;VAS pain score;Degree of knee joint swelling (leg circumference);Range of knee motion;Strength of lower limb muscles;LOS (length of stay);The incidence of adverse events;Intraoperative blood loss;Dominant blood loss;Hidden blood loss;Total perioperative blood loss;C-reactive protein;Interleukin - 6;

—

Countries

China

Contacts

Public ContactPengde Kang

West China Hospital, Sichuan University

kangpengd@163.com+86 18280213153

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026